{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T06:03:32Z","timestamp":1749621812101},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.4183","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T22:01:31Z","timestamp":1450130491000},"page":"3215-3219","source":"Crossref","is-referenced-by-count":12,"title":["Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years"],"prefix":"10.2169","volume":"54","author":[{"given":"Takashi","family":"Iijima","sequence":"first","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Sumida","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Mise","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kawada","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiharu","family":"Ueno","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamanoue","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Hayami","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikako","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenmei","family":"Takaichi","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"},{"name":"Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"},{"name":"Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 20: 636-647, 1993."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 10: 61-67, 1996.","DOI":"10.1097\/00002030-199601000-00009"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 66: 148-150, 2001.","DOI":"10.1002\/1096-8652(200102)66:2<148::AID-AJH1034>3.0.CO;2-P"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Simko R, Nagy K, Lombay B, et al. Multicentric Castleman disease and systemic lupus erythematosus phenotype in a boy with Klinefelter syndrome: long-term disease stabilization with interferon therapy. J Pediatr Hematol Oncol 22: 180-183, 2000.","DOI":"10.1097\/00043426-200003000-00021"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 55: 477-503, 2004.","DOI":"10.1146\/annurev.med.55.091902.104249"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98: 3473-3475, 2001.","DOI":"10.1182\/blood.V98.12.3473"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 102: 2786-2788, 2003.","DOI":"10.1182\/blood-2003-03-0951"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 82: 766-768, 2003.","DOI":"10.1007\/s00277-003-0718-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ide M, Ogawa E, Kasagi K, Kawachi Y, Ogino T. Successful treatment of multicentric Castleman's disease with bilateral orbital tumour using rituximab. Br J Haematol 121: 818-819, 2003.","DOI":"10.1046\/j.1365-2141.2003.04358.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 78: 302-305, 2005.","DOI":"10.1002\/ajh.20283"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Robinson D Jr, Reynolds M, Casper C, et al. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol 165: 39-48, 2014.","DOI":"10.1111\/bjh.12717"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106: 2627-2632, 2005.","DOI":"10.1182\/blood-2004-12-4602"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964, 2008.","DOI":"10.1182\/blood-2008-05-155846"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ikeda S, Chisuwa H, Kawasaki S, et al. Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum. J Clin Pathol 50: 965-967, 1997.","DOI":"10.1136\/jcp.50.11.965"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM 95: 211-218, 2002.","DOI":"10.1093\/qjmed\/95.4.211"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/24\/54_54.4183\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T01:36:07Z","timestamp":1498268167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/24\/54_54.4183\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":15,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.4183","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}